



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

			URGENT		
MEMBER INFORMATION					
LAST NAME:		FIRST NAME:			
PHONE NUMBER:		DATE OF BIRTH:			
STREET ADDRESS:					
CITY:		STATE: ZIP CODE:	:		
PATIENT INSURANCE ID NUN	/IBER:				
MALE FEMALE HEIGHT (IN/CM): WEIGHT (LB/KG): ALLERGIES: FYOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: https://magellanrx.com/member/external/commercial/common/doc/en-us/phi_disclosure_authorization.pdf					
PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE):					
PRESCRIBER INFORMATION					
LAST NAME:		FIRST NAME:			
PRESCRIBER SPECIALTY:		EMAIL ADDRESS:			
NPI NUMBER:		DEA NUMBER:			
PHONE NUMBER:		FAX NUMBER:			
STREET ADDRESS:					
CITY:		STATE: ZIP CODE:	:		
REQUESTOR (if different than prescriber):		OFFICE CONTACT PERSON:			
MEDICATION OR MEDICAL D	DISPENSING INFORMATION				
MEDICATION NAME:					
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:		
■ NEW THERAPY ■ RENEWAL		IF RENEWAL: DATE THERAP	Y INITIATED:		
DURATION OF THERAPY (SPE	CIFIC DATES):				

Continued on next page.







Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	LAST NAME: MEMBER'S FIRST NAME:	
1. HAS THE PATIENT TRIED ANY OTHER	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:
2. LIST DIAGNOSES:		ICD-10:
 □ Active ankylosing spondylitis □ Moderate to severely active psoriatic art □ Moderate to severely active rheumatoid □ Polyarticular juvenile idiopathic arthritis □ Other Diagnosis 		
3. REQUIRED CLINICAL INFORMATION PRIOR AUTHORIZATION.	: PLEASE PROVIDE ALL RELEVANT CLINIC	AL INFORMATION TO SUPPORT A
For <u>all diagnoses</u> , answer the following Will the patient be taking Simponi con Rituxan, Orencia, Cimzia, Enbrel, Hum	currently with another TNF antagonist	or biologic, such as Kineret, Remicade,
Select if Simponi is prescribed by the f Dermatologist Rheumatologist	ollowing specialists:	
☐ Yes ☐ No *Must submit dates of	equate response to at least a three mon fuse. equate response to at least a three mon	
☐ Yes ☐ No *Must submit dates of	· ·	un treatment with numma:
☐ Yes ☐ No *Must submit docume	et two (2) NSAIDS or does the patient han ntation.	
Has the patient tried and failed metho	trexate? □ Yes □ No *Must submit	documentation.
Has the patient had a trial and inadeq	ntic arthritis, also answer the following: uate response to oral disease-modifying yclosporine or leflunamide(Arava)?*	g anti-rheumatic agents (DMARDs)
	ologic DMARD due to chronic liver disea SH, or elevated liver enzymes?* □ Yes	
	se provide rationale (if applicable), expl severely active rheumatoid arthritis, als	

© 2017–2023 by Magellan Rx Management, LLC. All Rights Reserved. Revision Date: 08/22/2018 CAT0225 11.1.2020







Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:
For moderately to severely active rheumatoid arthritis, a Has the patient had a trial and inadequate response to modifying anti-rheumatic agent (DMARD) such as Imura *Must submit documentation.	
	er enzymes?* Yes No No Ie (if applicable), explaining why the patient is unable to
take a DMARD:	
For polyarticular juvenile idiopathic arthritis, also answe	r the following:
Has the patient tried and had an inadequate response or agent [e.g., methotrexate, sulfasalazine, or leflunomide	r intolerance to an oral disease modifying anti-rheumatic (Arava)]? Yes No
Is the patient unable to take a non-biologic DMARD due liver, nonalcoholic steatohepatitis/NASH, or elevated liv	
If "no" to the above question, provide the rationale expl DMARDs:	
Reauthorization:	
If this is a reauthorization request, answer the following Will the patient be taking Simponi concurrently with and Rituxan, Orencia, Cimzia, Enbrel, Humira, Actemra or Xel	other TNF antagonist or biologic, such as Kineret, Remicade,
Has the patient had a positive clinical response, and is re ☐ Yes ☐ No *Please provide documentation.	emission of disease maintained with continued use?*
Select if Simponi is prescribed by the following specialist Dermatologist Rheumatologist	s:
Are there any other comments, diagnoses, symptoms, mphysician feels is important to this review?	edications tried or failed, and/or any other information the
Please note: Not all drugs/diagnosis are covered on all plainformation is received.	ans. This request may be denied unless all required
ATTESTATION: I attest the information provided is true a the Health Plan, insurer, Medical Group or its designees n information necessary to verify the accuracy of the inform	··
Prescriber Signature or Electronic I.D. Verification:	Date:







Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:

CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Magellan Rx Management Prior Authorization Program

Attn: CP – 4201 P.O. Box 64811 St. Paul, MN 55164-0811

© 2017–2023 by Magellan Rx Management, LLC. All Rights Reserved. Revision Date: 08/22/2018 CAT0225 11.1.2020

